DOCSLIB.ORG

Proceedings of the Waikato Clinical Campus Biannual Research Seminar Wednesday 11 March 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proceedings of the Waikato Clinical Campus Biannual Research Seminar Wednesday 11 March 2020 PROCEEDINGS Proceedings of the Waikato Clinical Campus Biannual Research Seminar Wednesday 11 March 2020 Ablation of ventricular patients (inability to locate PVC Pain relief options in arrhythmias at origin in a patient with multiple labour: remifentanil different morphologies, inad- Waikato Hospital vertent aortic puncture with no PCA vs epidural Janice Swampillai,1 E Kooijman,1 M sequelae, PVC focus adjacent to Dr Jignal Bhagvandas,1 Symonds,1 A Wilson,1 His bundle, cardiogenic shock Mr Richard Foon2 1 1 1 RF Allen, K Timmins, A Al-Sinan, during anaesthesia). Endo- 1Whangarei Hospital, Whangarei; D Boddington,2 SC Heald,1 MK Stiles1 cardial ablation was done in 96 2Waikato Hospital, Hamilton. 1Waikato Hospital, Hamilton; patients and three patients also Objective 2Tauranga Hospital, Tauranga. underwent epicardial ablation Remifentanil is commonly Background (one patient underwent two used in obstetrics due to its Catheter ablation can be an epicardial procedures including fast metabolism time. It is effective treatment strategy one open chest procedure). an attractive option for IV for patients with ventricular General anaesthesia was used patient-controlled analgesia tachycardia (VT) or frequent in 46% of cases, conscious (PCA) in labour. We compared premature ventricular sedation was used in 54%. the effi cacy of IV Remifen- complexes (PVCs). The goal is to Sixty-two percent were elective tanil PCA with epidural during improve quality of life as well as procedures and 38% were labour. mortality. done acutely. The overall acute Method success rate was 91%, falling to Objectives Using a retrospective We aimed to characterise 75% at three months, 73% at six approach, we identifi ed a our population of patients who months and 68% at 12 months. total of 285 patients requiring have undergone ablation for Average procedure time was Remifentanil PCA presenting to ventricular arrhythmias over 180±64 minutes, fl uoroscopy Waikato delivery suite between the past six years, and report time 15±12 minutes, ablation the years 2017 to 2019. The outcomes of this procedure. time 22±19 minutes. The 30-day primary outcome measured complication rate post-pro- Methods was an assessment of patients cedure was 5.8%, occurring in We analysed data from requiring further epidural anal- seven patients. These compli- consecutive patients who gesia post-Remifentanil PCA. cations were two deaths, underwent VT/PVC ablation Secondary outcomes included three pericardial effusions from January 2014–February number requiring caesarean requiring pericardiocentesis, 2020. Medical and cardiac section, instrumental use and one stroke with full recovery, implantable electronic device number with a PPH or tear. This one groin haematoma which records were reviewed. was compared to 285 patients did not require intervention. Results requiring epidural analgesia. During the analysis period nine A total of 121 procedures Results patients died during follow up: were performed in 100 patients. We found 24% (68 of 285) of Mortality was 4.4% at three There were 73 males and 27 Remifentanil patients required months, 6.3% at six months, 9.1 females, mean age 60±13 years. an epidural post-PCA for further % at 12 months. The aetiology of ventricular pain relief. Of the epidural Conclusion arrhythmias was ischaemia patients, 1.75% (5 of 285) In patients with ventricular in 33 (33 males), non-isch- required a second epidural after arrhythmias, ablation is a safe aemic in 63 (38 males) and failing their fi rst (RR 13.6, 95% and feasible option to reduce mixed aetiology in four (two CI 5.57–33.22, P=0.0001, P<0.05). defi brillator therapy, hospital males). A single procedure was Nineteen percent (53 of 285) of admissions, heart failure and performed in 83 patients, 12 Remifentanil patients required mortality, but repeated proce- patients had two procedures caesarean section delivery dures are often needed. Our and fi ve had three procedures compared to 31% (89 of 285) results are comparable to inter- (17 patients had ≥1 procedure, of epidural patients (RR 0.595, national standards. giving a 14% redo rate). No 95% CI 0.442–0.802, P=0.0006, ablation was done in four P<0.05). Four percent (12 of NZMJ 12 June 2020, Vol 133 No 1516 ISSN 1175-8716 © NZMA 105 www.nzma.org.nz/journal PROCEEDINGS 285) of Remifentanil patients itative interviews have found Aortic size index required instrument use that families appreciate the predicts survival in compared to 11.2% (32 of 285) tool and have good engagement of epidural patients (RR 0.375, with staff and services they are patients with abdominal 95% CI 0.197–0.713, P=0.0028, referred to. aortic aneurysm P<0.05). 2.8% (8 of 285) of Su-Ann Yee,1 Zoë Vincent,2 Remifentanil patients had a The psychosocial needs Andrew Hill,2 Greg Jones,3 large PPH or tear compared of cancer patients in Manar Khashram4,5 to 3.5% (10 of 285) of epidural the Waikato region 1Faculty of Medical and Health patients (RR 0.800, 95% CI Sciences, University of Auckland, 1 1 1 0.320–1.998, P=0632, P>0.05). Paul N, Blackmore TL, Chepulis L, Auckland; 2Department of Vascular 2 2 1 Conclusion Burrett V, McCleery J, Lawrenson R Surgery, Auckland City Hospital, The results of this study 1Medical Research Centre, Auckland; 3Vascular Research confi rm some Remifentanil PCA University of Waikato, Hamilton; Group, Department of Surgical patients require epidural anal- 2Cancer Psychological and Social Sciences University of Otago, 4 gesia progression in labour. The Support Service, Waikato District Dunedin; Department of Vascu- rate of instrumental delivery Health Board, Hamilton. lar Surgery, Waikato Hospital, Hamilton; 5Department of Surgery and caesarean section was Cancer is a major health University of Auckland, Auckland. almost halved in the Remifen- concern in New Zealand. A Objective tanil PCA group when compared cancer diagnosis is associated Most factors infl uencing to the epidural group. This with elevated psychosocial abdominal aortic aneurysm fi nding supports the use of distress that negatively impacts (AAA) survival are well Remifentanil PCA in labour as on quality of life. The Ministry documented, however some an alternative to epidurals. of Health (MOH) recognises predictors such as BMI have the importance of screening produced contradictory results. for psychosocial distress A randomised It is well established that and providing psychosocial controlled trial of increased AAA diameter is asso- support as part of cancer care, Harti Hauora Tamariki, ciated with increased mortality yet screening is underuti- and rupture. Our hypothesis a holistic whānau- lised, resulting in a number of was to evaluate if the effect of centred approach, on patients with unmet psycho- AAA size relative to body size social needs. We investigated the paediatrics wards has an impact on survival after the characteristics and psycho- at Waikato Hospital AAA repair. social support needs of cancer Dr Nina Scott,1 patients in the Waikato region Methods 1,2 This was a retrospective Dr Polly Atatoa-Carr, who were referred to the 2 study evaluating patients with Dr Bridgette Masters-Awatere, Cancer Psychological and 1 a threshold (>5cm) AAA from Dr Amy Jones Social Support Service (CPSSS) Auckland City Hospital and 1Waikato District Health at the Waikato District Health 2 Waikato Hospital. Multisource Board, Hamilton ; University Board (DHB) between 2016 data was used to acquire patient of Waikato, Hamilton. and 2018. Data from the CPSSS information, including body size Problem were compared with Waikato measurements close to the time Too many tamariki Māori are regional data obtained from the of surgery. Logistic regression returning to hospital within one New Zealand Cancer Register and Cox-proportional models year of admission to Waikato (NZCR). Only 6% of cancer were used to analyse the 30-day Hospital. patients in the region were mortality and late survival, Solution referred to CPSSS. Age, gender, respectively. Harti Hauora Tamariki is a ethnicity and type of cancer whānau Māori-centric multi- were all signifi cant factors Results level programme to support associated with the likelihood There were 1,060 patients, wellbeing via engagement, of receiving a referral. Patients with a median age of 75 needs assessment using a with breast, haematological and years and 77% were females. screening tool and provision head and neck cancers were AAA diameter and body size of, or navigation to wellbeing the most likely to be referred, measurements were not asso- services. as were younger patients and ciated with 30 day mortality. The median follow-up was 4.5 years. Method females. Males and Māori were We conducted a less likely to be referred. The AAA diameter was a risk for randomised-controlled trial most common reasons patients late survival (Hazard ratio [HR]: recruiting over 980 whānau sought a psychosocial referral 1.18, 95% confi dence interval with a child (aged 0–4) admitted were psychological/emotional [CI]: 1.06–1.30). Increased to the acute paediatric ward at distress, family concerns and weight, body mass index and Waikato Hospital. Half were fear of treatment. Psychosocial body surface area were all randomised into the inter- distress is present in cancer protective against mortality (HR: vention group (Harti) and half patients in the Waikato, and 0.99, CI: 0.98–0.99; HR: 0.98, CI: had usual care. the CPSSS plays a vital role in 0.5–0.99; HR: 0.46, CI: 0.25–0.83). ASI values ranged from 1.4–7cm/ Results supporting the psychosocial m2 and increased ASI was asso- Quantitative results are not needs of cancer patients. ciated with increased mortality yet available. However, qual- (HR: 1.4, CI: 1.2–1.7). NZMJ 12 June 2020, Vol 133 No 1516 ISSN 1175-8716 © NZMA 106 www.nzma.org.nz/journal PROCEEDINGS Conclusion 12.0% receiving metformin or treatment in routine clinical Patients with a large AAA and insulin.
Load more

Recommended publications
  • Screening for Latent Tuberculous Infection in People Living with HIV Infection in Auckland, New Zealand
    INT J TUBERC LUNG DIS 21(9):1008–1012 Q 2017 The Union http://dx.doi.org/10.5588/jtld.17.0103 Screening for latent tuberculous infection in people living with HIV infection in Auckland, New Zealand N. Gow, S. Briggs, M. Nisbet Department of Infectious Diseases, Auckland City Hospital, Auckland, New Zealand SUMMARY SETTING: New Zealand, which has a low incidence of RESULTS: Of the 752 patients from the initial cohort, tuberculosis (TB), has historically taken a risk-based 416 (55%) had documentation of LTBI screening, which approach to screening for latent tuberculous infection was positive in 74 (10%): 19/461 (4%) low-risk and 55/ (LTBI) in adult people living with the human immuno- 291 (19%) high-risk patients. LTBI treatment was deficiency virus infection (PLHIV). received in 13 low-risk and 44 high-risk patients. Of OBJECTIVE: To evaluate LTBI screening, treatment and 73 patients in the second cohort, 68 (93%) were outcomes in an adult PLHIV population. screened. DESIGN: This was a retrospective clinical record review CONCLUSION: LTBI screening was incomplete in our of an initial cohort of adult PLHIV attending the clinic, but improved between 2011 and 2014. A Auckland City Hospital HIV clinic in 2011, and a significant number of patients with LTBI did not second cohort of adult PLHIV newly attending the clinic originate from a high TB incidence country. in 2014. We analysed high-risk (born in or acquiring KEY WORDS: PLHIV; high-income countries; screen- HIV in a high TB incidence country) and low-risk ing; IGRA patients using descriptive statistical methods.
    [Show full text]
  • New Zealand Out-Of-Hospital Acute Stroke Destination Policy Northland and Auckland Areas
    New Zealand Out-of-Hospital Acute Stroke Destination Policy Northland and Auckland Areas This policy is for the use of clinical personnel when determining the destination hospital for patients with an acute stroke in the out-of-hospital setting in the Northland and Auckland areas of New Zealand. It has been developed by the Northern Region Stroke Network in conjunction with the National Stroke Network and the Ambulance Sector. Publication date October 2020 Acute Stroke Destination Flowchart: Auckland Area Does the patient have signs or symptoms Stroke is unlikely, treat of an acute stroke? NO appropriately without YES using this policy. Perform additional screening using the PASTA tool Will the patient arrive at: NO NO A stroke hospital within 4 hours Does the patient Transport to the of symptom onset, or meet ‘wake-up’ most appropriate Auckland City Hospital within stroke criteria?1 hospital. 6 hours of symptom onset? YES YES Transport to the catchment YES PASTA positive? NO area hospital and notify hospital personnel of the Patient will arrive in ED 0800–1600, Mon–Fri following information: PASTA results and Transport to the most appropriate stroke hospital and notify hospital personnel as below: FAST results and Time of symptom onset and North Shore Hospital. Auckland City Hospital. NHI number Waitakere Hospital. Middlemore Hospital. Out of hours If the patient is in the North Shore Hospital, Notify hospital personnel Waitakere Hospital or Middlemore Hospital ASAP and provide the catchment: following information as a – Phone the on-call neurologist at Auckland City minimum: Hospital on 0800 1 PASTA as per the PASTA tool.
    [Show full text]
  • Medical Register
    No. 5.4,· 1335 SUPPLEMENT TO THE NEW ZEALAND GAZETTE OF THURSDAY, 5 SEPTEMBER 1963 Published by Authority WELLINGTON: MONDAY, 9 SEPTEMBER 1963 NEW ZEALAND MEDICAL REGISTER 1963 .1336 THE NEW ZEALAND GAZETTE No. 54 MEDICAL COUNCIL E. G. SAYERS, Esq., C.M.G., M.D., CH.B.(N.Z.), F.R.C.P.(LOND.), HON.F.R.C.P.(EDIN.), F.R.A.C.P., HON.F.A.C.P., D.T.M. and H.(LOND.), F.R.S.(N.Z.), Chairman. H. B. TURBOTT, Esq., I.S.0., M.B., CH.B.(N.Z.), D.P.H.(N.Z.). Sir DOUGLAS ROBB, C.M.G., M.D., CH.M.(N.Z.), F.R.C.S.(ENG.), L.R.C.P.(LOND.), F.R.A.C.S., HON.F.A.C.S., F.R.S.(N.Z.), HON.LL.D., Q.U.BELF., Deputy Chairman. J. O. MERCER, Esq., C.B.E., M.B., CH.B.(N.Z.), F.R.C.P.(LOND.), F.R.A.C.P. J. A. D. IVERACH, Esq., M.C., M.B., CH.B.(N.Z.), F.R.C.P.(EDIN.), F.R.A.C.P. C. L. E. L. SHEPPARD, Esq., E.D., B.A., M.B., CH.B.(N.Z.), F.R.C.S.(EDIN.). A. J. MASON, Esq., M.B., CH.M.(N.Z.), F.R.C.S.(ENG.), F.R.A.C.S. SECRETARY K. A. G. HINDES, Esq., Care of District Health Office, Private Bag, Wellington C. 1., N.Z., Tel. 71049 9 SEPTEMBER THE NEW ZEALAND GAZETTE 1337 Medical Register THE following provisions of the Medical Practitioners Act 1950 are published for general information: Subsections (1) and (2) of section 29: Subsection (1)- "The Secretary to the Council shall, as at the thirtieth day of June in the year nineteen hundred and fifty-one and in each year thereafter, prepare a copy of the register of persons who are registered as medical practitioners or conditionally registered under this Act, and shall certify it to be a true copy, and shall cause it to be published in the Gazette as soon as practicable after the thirtieth day of June in the year to which the copy relates." Subsection (2)- "The copy of the register shall indicate with reference to every person whose name appears therein whether the person is the holder of an annual practising certificate for the then current year, and whether he is registered as a medical practitioner or conditionally registered.
    [Show full text]
  • Applicant Guide 2014/2015
    Applicant Guide 2014/2015 Table of Contents Introduction ........................................................................................................................................... 3 ACE Principles ...................................................................................................................................... 3 Overview of the ACE Recruitment Process .......................................................................................... 4 Eligibility for ACE scheme .................................................................................................................... 5 How to apply ......................................................................................................................................... 6 How to use the online ACE application system .................................................................................... 8 Special requirements for ACE applicants ........................................................................................... 13 How the ACE match algorithm works ................................................................................................. 14 ACE CV Template .............................................................................................................................. 15 RMO Unit/Recruitment Contacts - North Island ................................................................................. 17 RMO Unit/Recruitment Contacts - South Island ................................................................................
    [Show full text]
  • Community to Hospital Shuttle Service
    Is other transport assistance Total Mobility Scheme available? The Total Mobility Scheme is a subsidised taxi Best Care for Everyone Yes, there are several options available to those service. The scheme is available to people who qualify. who are unable to use public transport due to the nature of their disability. It works using vouchers that give a 50% discount on normal National Travel Assistance (NTA) Policy taxi fares. The scheme is part-funded by the NTA helps with travel costs for people who New Zealand Transport Agency and managed need to travel often or for long distances to get by the local authorities. to specialist health or disability services. The MAXX Contact Centre can provide the To receive this service, you need to be referred contact details for disability agencies that by your specialist (not your family doctor) to process applications. Call 09 366 6400 see another specialist or to receive specialist services. Both the specialists must be part of a St John Health Shuttle - Waitakere service funded by the government. The St John Health Shuttle provides safe, For example, this could be a renal dialysis reliable transport for Waitakere City residents centre, a specialist cancer service or a child to and from appointments with family doctors, development service. The rules are different treatment at Waitakere Hospital outpatient for children and adults, and for those holding clinics, visits to specialists, and transport to a Community Services Card. Sometimes, a and from minor day surgery. The vehicle is support person can receive assistance too. wheelchair accessible. The service operates Monday to Friday for appointments between How do I contact NTA? 9.30am and 2pm.
    [Show full text]
  • Initial Experience with Dabigatran Etexilate at Auckland City Hospital
    THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association CONTENTS This Issue in the Journal 4 A summary of the original articles featured in this issue Editorial 7 A call for collaboration on inflammatory bowel disease in New Zealand Russell Walmsley Original Articles 11 The cost of paediatric and perianal Crohn’s disease in Canterbury, New Zealand Michaela Lion, Richard B Gearry, Andrew S Day, Tim Eglinton 21 Screening for Mycobacterium tuberculosis infection among healthcare workers in New Zealand: prospective comparison between the tuberculin skin test and the QuantiFERON-TB Gold In-Tube® assay Joshua T Freeman, Roger J Marshall, Sandie Newton, Paul Austin, Susan Taylor, Tony C Chew, Siobhan Gavaghan, Sally A Roberts 30 Audit of stroke thrombolysis in Wellington, New Zealand: disparity between in-hours and out-of-hours treatment time Katie Thorne, Lai-Kin Wong, Gerard McGonigal 37 Training medical students in Pacific health through an immersion programme in New Zealand Faafetai Sopoaga, Jennie L Connor, John D Dockerty, John Adams, Lynley Anderson 46 Insomnia treatment in New Zealand Karyn M O’Keeffe, Philippa H Gander, W Guy Scott, Helen M Scott 60 Evaluation of New Zealand’s bicycle helmet law Colin F Clarke 70 Sun protection policies and practices in New Zealand primary schools Anthony I Reeder, Janet A Jopson, Andrew Gray Viewpoint 83 Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand? Mark J Bolland, Andrew Grey, James S Davidson, Tim Cundy, Ian R Reid NZMJ 10 February 2012, Vol 125 No 1349; ISSN 1175 8716 Page 1 of 126 http://journal.nzma.org.nz/journal/125-1349/5068/ ©NZMA Clinical Correspondence 92 A case of yellow fever vaccine-associated disease Heather Isenman, Andrew Burns 96 An unusual cause of carotid sinus hypersensitivity/syndrome Donny Wong, Joey Yeoh 99 Medical image.
    [Show full text]
  • New Zealand Telehealth Stocktake
    New Zealand Telehealth Stocktake District Health Boards Promoting sustainable telehealth August 2014 New Zealand Telehealth Stocktake 2014 Phase 1: DHBs Prepared by: Pat Kerr, Principal Consultant, NZ Telehealth Forum Patricia Kerr and Associates / Telehealth NZ Ltd [email protected] Mob +64 21 921 265 Acknowledgments: National Telehealth Leadership Group members for input to survey design and testing, and for review of the draft report. National Health IT Board for support in survey distribution and recording responses. DHB respondents for their time in completing the surveys, and for their interest in telehealth. Terri Hawke, Telehealth Forum Project Coordinator, for data and report formatting and graphics. NZ Telehealth Forum: To find out more about the NZ Telehealth Forum and resources, visit http://ithealthboard.health.nz/telehealthforum. NZ Telehealth Forum Stocktake – Phase 1 DHBs August 2014 Page i New Zealand Telehealth Stocktake 2014 Phase 1: DHBs Contents Executive summary ................................................................................................................................... 1 Summary of results............................................................................................................................................ 2 Commentary ....................................................................................................................................................... 7 Next steps ..........................................................................................................................................................
    [Show full text]
  • Bloodstream Infection with Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae at a Tertiary Care Hospital in New Zeal
    International Journal of Infectious Diseases 16 (2012) e371–e374 Contents lists available at SciVerse ScienceDirect International Journal of Infectious Diseases jou rnal homepage: www.elsevier.com/locate/ijid Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes a, b c d Joshua T. Freeman *, Stephen J. McBride , Mitzi S. Nisbet , Greg D. Gamble , a e b Deborah A. Williamson , Susan L. Taylor , David J. Holland a Department of Clinical Microbiology, LabPlus, PO Box 110031, Auckland City Hospital, Auckland 1148, New Zealand b Department of Medicine, Middlemore Hospital, Auckland, New Zealand c Department of Infectious Diseases, Auckland City Hospital, Auckland, New Zealand d Department of Biostatistics, University of Auckland, Auckland, New Zealand e Department of Clinical Microbiology, Middlemore Hospital, Auckland, New Zealand A R T I C L E I N F O S U M M A R Y Article history: Objectives: To define local risk factors and outcomes for bacteremia with extended-spectrum beta- Received 26 July 2011 lactamase-producing Enterobacteriaceae (ESBL-E) at a tertiary hospital in New Zealand. Received in revised form 30 November 2011 Methods: Patients with ESBL-E bacteremia were compared to matched control patients with non-ESBL- Accepted 11 January 2012 producing Enterobacteriaceae bacteremia. Patients were matched by onset of bacteremia (community vs. Corresponding Editor: Karamchand Ramo- hospital), site of blood culture collection (peripheral vs. via central line), and infecting organism species. tar, Ottawa, Canada Results: Forty-four cases with matched controls were included. Eight- and 30-day mortality was higher in cases than controls (27% vs.
    [Show full text]
  • Clinical Perfusionist Waikato Hospital, Hamilton, NZ WAI12860
    Clinical Perfusionist Waikato Hospital, Hamilton, NZ WAI12860 Live and work in the stunningly beautiful Waikato region; an ideal place to experience the authentic friendly Kiwi lifestyle. About the role: We are looking for an experienced, dynamic, motivated, and enthusiastic perfusionist to join our team of Clinical Perfusion Scientists. This is a permanent role, working 80 hours per fortnight with flexible rosters with on-call commitment. You will join a busy department of experienced staff who deliver an excellent standard of service for Cardiopulmonary Bypass, Cell Salvage, Intra-Aortic Balloon Counter pulsation and occasional Hybrid lab and ECMO provision. Experience in the latter is desirable but not essential as the necessary training and support will be provided. You will be expected to deliver a high standard of patient care and integrate completely with the existing perfusion team, as well as the wider theatre team. To be considered for this position you must be accredited by one of the following Society of Clinical Perfusionist Scientists: • ABCP – Australasian Board of Clinical Perfusion • CCPS GBI – College of Clinical Perfusion Scientists Great Britain and Ireland • EBCP – European Board of Clinical Perfusion • ABCP – American Board of Clinical Perfusion About us: Waikato Hospital in Hamilton is one of New Zealand’s largest tertiary, teaching hospitals with over 600 inpatient beds and 22 operating theatres. Clinical specialities include Women’s and Children Services, Cardiology / Cardiothoracic Surgery, Oncology and Haematology, Surgical services, and Mental Health and Addiction. Waikato Hospital is the Midland regional referral centre for multiple specialties including trauma surgery, oncology, and neurology. Your application: To review the position description and apply, please visit the Waikato District Health Board website: https://tas-adhbrac.taleo.net/careersection/.wai_ext/jobdetail.ftl?lang=en&job=wai12860 For any queries about the role please contact Tina Gupwell, [email protected].
    [Show full text]
  • For Peer Review Journal: Clinical Endocrinology
    Clinical Endocrinology A low incidence of io dine -induced hyperthyroidism following administration of iodinated contrast in an iodine deficient region For Peer Review Journal: Clinical Endocrinology Manuscript ID: Draft Manuscript Type: 3 Original Article - Australia, Japan, SE Asia Date Submitted by the Author: n/a Complete List of Authors: Jarvis, Carol; Waikato Hospital, Endocrinology Simcox, Kim; Waikato Hospital, Department of Radiology Tamatea, Jade; Waikato Hospital, Department of Endocrinology; University of Auckland, Waikato Clinical School McAnulty, Kim; Waikato Hospital, Department of Radiology Meyer-Rochow, Goswin; Waikato Hospital, Department of Surgery; University of Auckland, Waikato Clinical School Conaglen, John; Waikato Hospital, Endocrinology; University of Auckland, Waikato Clinical School Elston, Marianne; Waikato Clinical School, University of Auckland; Waikato Hospital, Department of Endocrinology Goiter, nodular < Conditions: < Thyroid, Hyperthyroidism < Conditions: < Key Words: Thyroid, Iodine deficiency < Conditions: < Thyroid, Thyroid function tests < Investigations & Rx: < Thyroid Page 1 of 21 Clinical Endocrinology 1 2 3 A low incidence of iodine-induced hyperthyroidism following administration of 4 5 iodinated contrast in an iodine deficient region 6 7 8 9 10 Short title: Low incidence of hyperthyroidism following iodinated contrast. 11 12 13 14 Carol Jarvis 1, Kim Simcox 2, Jade AU Tamatea 1, Kim McAnulty 2, Goswin Y Meyer- 15 16 Rochow 3,4 , John V Conaglen 1, Marianne S Elston 1,4 17 18 Departments Forof
    [Show full text]
  • Some Personal Overviews by Hugh Jamieson Bruce White Ray Trott
    b The development of MEDICAL PHYSICS and BIOMEDICAL ENGINEERING in NEW ZEALAND HOSPITALS 1945-1995 _____________ Some personal overviews by Hugh Jamieson Bruce White Ray Trott Jack Tait Gordon Monks __________ Editor H D Jamieson ___________ Second edition First published 1995 Second edition 1996 Reprinted 2006 ISBN 0-476-01437-9 ii CONTENTS Second edition Index of photographs; Staff lists .. .. .. .. iv Preface, and Preface to Second Edition .. .. .. 1 Introduction .. .. .. .. .. .. .. 2 Early hospital physics in NZ: "Some memory fragments" 3 Around the centres (first appointments in the 6 centres) 7 Supervoltage radiotherapy (summary) .. .. .. 8 Nuclear medicine (summary) .. .. .. .. .. 12 Nuclear medicine imaging (summary) .. .. .. 14 Biomedical engineering (summary) .. .. .. .. 15 Computing in hospitals (summary) .. .. .. .. 18 The ongoing developments (summary); Conclusion .. 20 Photograph, 1954 inaugural NZMPA meeting, Christchurch 21 Hospital/Medical Physics in Dunedin - Hugh Jamieson 23 Wellington Hospital - Medical Physics and Biomedical Engineering .. 62 Hospital Physics Beginnings at Auckland Hospital .. 68 The History of Nuclear Medicine in Auckland -Bruce White 71 Auckland Hospital...Medical Physics & Clinical Engineering - Bruce White 83 Hospital/Medical Physics at Palmerston North Hospital - Ray Trott 97 Medical Physics & Bioengineering at Christchurch Hospital - Jack Tait 108 Hospital Physics / Scientific Services at Waikato Hospital - Gordon Monks 135 Retrospect and contemplation .. .. .. .. 151 = = = = = = = = = = =
    [Show full text]
  • ADHB Neurology House Officer Run Description
    RUN DESCRIPTION POSITION: HOUSE OFFICER DEPARTMENT: Neurology PLACE OF WORK: Auckland City Hospital RESPONSIBLE TO: Business Manager Neuroservices through the Clinical Director Neurology and Clinical Neurophysiology Service FUNCTIONAL Healthcare consumer, Hospital and community based healthcare workers RELATIONSHIPS: PRIMARY OBJECTIVE: To facilitate the management of patients under the care of the Neurology Service. RUN RECOGNITION: Recognised as Category B for the purposes of registration by the Medical Council of New Zealand RUN PERIOD: 3 months Section 1: House Officer’s Responsibilities Area Responsibilities General Facilitate the management of inpatients commensurate with and appropriate to the house officer’s skill level; Manage the assessment and admission of acute and elective patients under the care of his/her team. Undertake clinical responsibilities as directed by the Registrar or Consultant, also organise relevant investigations, ensure the results are followed up, sighted and electronically signed; Be responsible, under the supervision of the Registrar and/or Consultant, to review inpatients on a daily basis (with the exception of unrostered weekends); Plan and deliver active anticancer treatment (as directed) Maintain a high standard of communication with patients, patients’ families and staff; Inform registrars/consultants of the status of patients especially if there is an unexpected event; Liaise with other staff members, departments, and General Practitioners in the management of in-patients; Communicate with patients and (as appropriate) their families about patients’ illness and treatment Prepare required paperwork on Friday prior to known or likely weekend discharges. Attend handover, Team and departmental meetings as required. ADHB Neurology House Officer Run Description- Effective 25 November 2013 Disclaimer: Please note that this run description is current at time of publication, however this information can be subject to change.
    [Show full text]